Notes Payable (Details Narrative) - USD ($) |
1 Months Ended | 6 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 21, 2017 |
Feb. 02, 2017 |
Nov. 03, 2016 |
Mar. 31, 2016 |
Jun. 29, 2015 |
Feb. 02, 2015 |
Mar. 31, 2017 |
Jun. 30, 2017 |
May 31, 2017 |
Mar. 15, 2017 |
Mar. 13, 2017 |
Mar. 07, 2017 |
Dec. 31, 2016 |
Sep. 15, 2016 |
Jun. 30, 2016 |
Feb. 03, 2015 |
|
| Consideration received | $ 5,000,000 | |||||||||||||||
| Estimated value of accounts receivable | $ 8,700,000 | |||||||||||||||
| Adjustment value of debt | $ 0 | $ 1,500,000 | ||||||||||||||
| Investment percentage | 20.00% | |||||||||||||||
| Debt term | 6 months | |||||||||||||||
| Repayment of debt | $ 500,000 | |||||||||||||||
| Debt instrument description | All payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty has not been paid $6.0 million, the Company was required to pay the difference, plus 30% interest per annum on the total balance. To date, the Company has not recovered any payments against the accounts receivable. | |||||||||||||||
| Accrued expenses | 1,500,000 | |||||||||||||||
| Due to related party | 6,500,000 | |||||||||||||||
| Debt instrument face amount | $ 10,850,000 | $ 1,600,000 | ||||||||||||||
| Debt instrument conversion price | $ 2.58 | |||||||||||||||
| Warrant to purchase common stock | $ 2.58 | |||||||||||||||
| Warrants exchanged for shares | 100,000 | 29,518 | ||||||||||||||
| Debt instrument periodic payment | $ 400,000 | |||||||||||||||
| Loan outstanding | $ 200,000 | |||||||||||||||
| Alcimede LLC [Member] | ||||||||||||||||
| Debt instrument maturity date | Feb. 02, 2016 | |||||||||||||||
| Common stock exercise price | $ 2.50 | |||||||||||||||
| Due from related party | $ 3,000,000 | |||||||||||||||
| Debt instrument interest rate | 6.00% | |||||||||||||||
| Debt instrument extended due date | Aug. 02, 2017 | |||||||||||||||
| Loan outstanding | $ 2,500,000 | |||||||||||||||
| Repayment of common stock | $ 300,000 | |||||||||||||||
| Mr Lagan [Member] | ||||||||||||||||
| Repayment of debt | $ 50,000 | 100,000 | ||||||||||||||
| Debt instrument extended due date | Feb. 02, 2018 | |||||||||||||||
| Stockholder [Member] | ||||||||||||||||
| Due to related party | 75,000 | |||||||||||||||
| Mr Diamantis [Member] | ||||||||||||||||
| Due to related party | $ 200,000 | |||||||||||||||
| Debt instrument face amount | $ 3,800,000 | |||||||||||||||
| Warrants exchanged for shares | 415,000 | |||||||||||||||
| Debt instrument interest rate | 10.00% | 10.00% | ||||||||||||||
| TCA Debenture [Member] | ||||||||||||||||
| Repayment of debt | 750,000 | |||||||||||||||
| Accrued and unpaid interest | 100,000 | $ 400,000 | ||||||||||||||
| Debt instrument fee | $ 150,000 | |||||||||||||||
| Debt instrument maturity date | Jun. 27, 2017 | |||||||||||||||
| TCA Debenture [Member] | April 2017 Through September 2017 [Member] | ||||||||||||||||
| Repayment of debt | $ 2,600,000 | |||||||||||||||
| September 2016 Notes [Member] | ||||||||||||||||
| Debt instrument conversion price | $ 7.50 | |||||||||||||||
| Warrant to purchase common stock | 66,667 | |||||||||||||||
| Common stock exercise price | $ 12.00 | |||||||||||||||
| Warrants exchanged for shares | 400,000 | |||||||||||||||
| September 2016 Notes [Member] | Two Investor [Member] | ||||||||||||||||
| Debt instrument face amount | $ 400,000 |